Reviewing Silexion Therapeutics (NASDAQ:SLXN) & CG Oncology (NASDAQ:CGON)

Silexion Therapeutics (NASDAQ:SLXN) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Analyst Ratings

This is a summary of recent recommendations and price targets for Silexion Therapeutics and CG Oncology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	0	0	1	0	3.00
CG Oncology	0	0	8	1	3.11

Silexion Therapeutics presently has a consensus price target of $9.00, indicating a potential upside of 965.21%. CG Oncology has a consensus price target of $65.14, indicating a potential upside of 133.91%. Given Silexion Therapeutics’ higher possible upside, analysts plainly believe Silexion Therapeutics is more favorable than CG Oncology.

Profitability

This table compares Silexion Therapeutics and CG Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	N/A	-249.43%
CG Oncology	-10,642.98%	-18.97%	-15.36%

Valuation and Earnings

This table compares Silexion Therapeutics and CG Oncology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	$260,000.00	N/A	N/A
CG Oncology	$200,000.00	10,588.57	-$48.61 million	N/A	N/A

Silexion Therapeutics has higher earnings, but lower revenue than CG Oncology.

Institutional & Insider Ownership

10.9% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 33.0% of Silexion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

CG Oncology beats Silexion Therapeutics on 6 of the 11 factors compared between the two stocks.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.